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Development of a Novel Clinical Pathway for
Evaluating Abnormal Bleeding Girls and Young Women
Christie Atchison
Lehigh Valley Health Network, Allentown, PA

Introduction/Background
Von Willeband disease (vWD) is the most
common inherited bleeding disorder,
affecting about 1% of the population.
Patients with vWD suffer from bruising,
skin bleeding, epistaxis, prolonged
mucosal bleeding, and prolonged
bleeding after dental procedures.
Though vWD has a prevalence of 1% in
the population, only a fraction of these
patients are diagnosed as having vWD.
This gap in prevalence and diagnosis is
caused in part by the reasonably mild
nature of type 1 vWD, which accounts
for the majority of cases; however,
some patients remain undiagnosed
secondary to failure of clinical recognition
of the disease due to lack of bleeding
challenges or failure to recognize minor
excessive bleeding such as menorrhagia.
The morbidity and mortality of patients
with vWD is particularly concerning
in young women and girls due to
an increase in complications during
menstruation, pregnancy, and potentially
life threatening complications during
delivery or the post-partum period. Due
to the potential for significant morbidity
and mortality in undiagnosed patients
and the existence of readily available
treatment Healthy People 2020 has
called for an increase in the proportion
of persons with hemoglobinopathies who
are referred for evaluation and treatment,
who receive early and continuous
screening for complications, and who
receive disease-modifying therapies.

Methodology
Development of a novel clinical pathway began with an extensive literature search
to solidify information regarding vWD. This review provided information on when
and what to test for, as well as, actionable steps to take regarding these test results.
After the literature search was complete, a novel pathway was developed in order
to facilitate a tool for guiding clinical decision. Pathway development was aimed at
primary care providers and other healthcare providers of adolescent women and
children. The pathway was completed and reviewed for accuracy and ease of use.

Results Gathered
Our search of current literature identified screening questions with high sensitivity for
vWD. These questions were paired with proper initial testing for patients identified as
“high risk” for vWD. A clinical pathway was designed to incorporate this information as
well as to guide clinical decision making once test results were returned (Figure 1).

Problem Statement
The objective of this Capstone project
is to raise awareness of vWD among
healthcare providers of girls and young
women and to develop a novel clinical
pathway to guide physician decisions in
screening and testing for vWD.

Conclusions and Future Implications
The objective of this Capstone project is to raise awareness of vWD among healthcare
providers of girls and young women and to develop a novel clinical pathway to guide
physician decisions in screening and testing for vWD.
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